L-精氨酸与5-甲氧基-3-(1-甲基乙氧基)-1-苯基-N-1H-四唑-5-基-1H-吲哚-2-甲酰胺的化合物(1:1) | 121530-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: L-精氨酸与5-甲氧基-3-(1-甲基乙氧基)-1-苯基-N-1H-四唑-5-基-1H-吲哚-2-甲酰胺的化合物(1:1)
• 英文名称: 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-YL-1H-indole-2-carboxamide arginine
• 英文别名: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;5-methoxy-1-phenyl-3-propan-2-yloxy-N-(2H-tetrazol-5-yl)indole-2-carboxamide
• CAS: 121530-58-3
• 化学式: C₆H₁₄N₄O₂*C₂₀H₂₀N₆O₃
• 分子量: 566.62
• InChiKey: OHOCQQJBKBVAFF-VWMHFEHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.64
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  235
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide 生成 L-精氨酸与5-甲氧基-3-(1-甲基乙氧基)-1-苯基-N-1H-四唑-5-基-1H-吲哚-2-甲酰胺的化合物(1:1)
  参考文献：
  名称：

  CONNOR, DAVID T.;UNANGST, PAUL C.;STABLER, S. RUSSELL

  摘要：

  DOI：

文献信息

• Acidic tetrazolyl substituted indole compounds and their use as
  申请人：Warner-Lambert Company

  公开号：US04675332A1

  公开（公告）日：1987-06-23

  Novel acidic indole compounds having use as antiallergic agents, methods of synthesis, compositions, and uses are claimed.

  声称拥有作为抗过敏剂使用的新型酸性吲哚化合物，合成方法，组成物和用途。
• THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY, METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY, AND SCREENING METHOD FOR THERAPEUTIC OR PROPHYLACTIC SUBSTANCE FOR RETINOPATHY OF PREMATURITY
  申请人：Japan Innovative Therapeutics, Inc.

  公开号：EP2913062A1

  公开（公告）日：2015-09-02

  Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.

  本发明提供了一种适合早产儿视网膜病变（ROP）致病机制的早产儿视网膜病变（ROP）治疗剂或预防剂，以及一种检测早产儿视网膜病变的方法。早产儿视网膜病变的治疗剂或预防剂使用至少一种由肥大细胞胰蛋白酶抑制剂和/或肥大细胞稳定剂组成的组中的物质作为活性成分。这种检测方法包括检测来自患者的生物样本中肥大细胞脱颗粒释放的标记物质，并根据检测到的标记物质的量来确定是否患有视网膜病变。
• Therapeutic or prophylactic agent for retinopathy of prematurity, testing method for retinopathy of prematurity, and screening method for therapeutic or prophylactic substance for retinopathy of prematurity
  申请人：TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY

  公开号：US10330670B2

  公开（公告）日：2019-06-25

  Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.

  本发明提供了一种适合早产儿视网膜病变（ROP）致病机制的早产儿视网膜病变（ROP）治疗剂或预防剂，以及一种检测早产儿视网膜病变的方法。治疗或预防早产儿视网膜病变的药物使用至少一种由肥大细胞胰蛋白酶抑制剂和/或肥大细胞稳定剂组成的组中的物质作为活性成分。这种检测方法包括检测来自患者的生物样本中肥大细胞脱颗粒释放的标记物质，并根据检测到的标记物质的量来确定是否患有视网膜病变。
• CONNOR, DAVID T.;UNANGST, PAUL C.;STABLER, S. RUSSELL
  作者：CONNOR, DAVID T.、UNANGST, PAUL C.、STABLER, S. RUSSELL

  DOI：——

  日期：——
• THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY
  申请人：Japan Innovative Therapeutics, Inc.

  公开号：EP2913062B1

  公开（公告）日：2019-05-08